Semaglutide + Tesamorelin: the stack guide
Semaglutide paired with Tesamorelin is a body-recomposition stack. Semaglutide drives weight loss; Tesamorelin specifically targets visceral adipose tissue (VAT) and counteracts the lean-mass loss that GLP-1 monotherapy is known to produce.
Why Semaglutide and Tesamorelin pair well
Semaglutide reduces overall caloric intake via appetite suppression, which reliably produces both fat and lean-mass loss. Tesamorelin is a GHRH analog clinically shown to reduce visceral fat and improve IGF-1 — helping preserve lean tissue while amplifying the fat-loss signal, particularly around the abdomen.
Suggested cadence
Standard Semaglutide titration (0.25 → 2.4 mg weekly). Tesamorelin 1–2 mg subcutaneous daily (typically pre-bed). Full protocol cycles are usually 12–24 weeks with monitoring of IGF-1 and fasting glucose every 4–6 weeks.
This is informational only — dosing should always be individualized and discussed with a qualified clinician.
Reconstitution notes
Semaglutide: A common ratio is 2 ml of bacteriostatic water for a 5 mg vial. Open the Semaglutide calculator →
Tesamorelin: A common ratio is 2 ml of bacteriostatic water for a 5 mg vial. Open the Tesamorelin calculator →
Side effects to watch for
Tesamorelin can raise fasting glucose and IGF-1; Semaglutide lowers glucose. Monitor both. Combined hunger suppression plus GH-axis stimulation can disrupt sleep for some users. Neither should be used during pregnancy or with active malignancy.
The two compounds
Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It slows gastric emptying…
Tesamorelin
Tesamorelin is a stabilized analog of human GHRH, FDA approved for reducing excess visceral adipose tissue in HIV-associated lipodystroph…
Track this stack on iPhone
Peptide Protocol schedules both compounds, calculates reconstitution, and rotates injection sites automatically.
See the app →Frequently asked questions
Why stack Semaglutide with Tesamorelin?
Semaglutide paired with Tesamorelin is a body-recomposition stack. Semaglutide drives weight loss; Tesamorelin specifically targets visceral adipose tissue (VAT) and counteracts the lean-mass loss that GLP-1 monotherapy is known to produce.
What is the typical Semaglutide + Tesamorelin dose?
Standard Semaglutide titration (0.25 → 2.4 mg weekly). Tesamorelin 1–2 mg subcutaneous daily (typically pre-bed). Full protocol cycles are usually 12–24 weeks with monitoring of IGF-1 and fasting glucose every 4–6 weeks.
Can you inject Semaglutide and Tesamorelin in the same syringe?
Many users co-administer GHRH + GHRP pairs (like CJC-1295 + Ipamorelin) in a single syringe to reduce injections, since both are stable in bacteriostatic water for short periods. For other pairs, draw and inject separately to minimize compatibility risk and to attribute any reaction to the correct compound.
What side effects should I watch for?
Tesamorelin can raise fasting glucose and IGF-1; Semaglutide lowers glucose. Monitor both. Combined hunger suppression plus GH-axis stimulation can disrupt sleep for some users. Neither should be used during pregnancy or with active malignancy.
How long should a Semaglutide + Tesamorelin cycle run?
Most user-reported cycles run 4–12 weeks depending on the goal. GH-axis stacks are typically cycled with a break of 4 weeks or more between blocks to preserve receptor sensitivity. Soft-tissue stacks are usually run continuously until the injury resolves.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.